Double Positivity for HPV DNA/P16
| Autor: | Ubai, Alsharif, Marvin, Hofmann, Maximilian, Gebhard, Lars, Tharun, Dirk, Rades, Peter, Sieg, Samer G, Hakim |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Time Factors Squamous Cell Carcinoma of Head and Neck Papillomavirus Infections Alphapapillomavirus Middle Aged Immunohistochemistry Disease-Free Survival Human Papillomavirus DNA Tests Predictive Value of Tests Germany DNA Viral Biomarkers Tumor Prevalence Humans Female Mouth Neoplasms Cyclin-Dependent Kinase Inhibitor p16 In Situ Hybridization Aged |
| Zdroj: | Anticancer research. 41(11) |
| ISSN: | 1791-7530 |
| Popis: | We investigated the prevalence of human papillomavirus (HPV) in a prospective cohort of patients with squamous cell carcinoma of the oral cavity (OSCC) using both p16Samples from 280 OSCC patients were analyzed for HPV-positivity using p16Specimen from 30 (10.7%) patients were p16+ and HPV DNA+, while 31 (11.0%) were either p16+ or HPV DNA+ only. OS probabilities at five years for HPV-positive and -negative groups were 50.9% (35.4%-73.1%) and 52.9% (47.0%-59.5%), respectively. HPV double positivity influenced neither OS, CSS nor DFS: HR=0.84 (0.43-1.63), 1.64 (0.76-3.54) and 1.13 (0.55-2.35), respectively.In contrast to oropharyngeal cancer, the prevalence of HPV in OSCC is low and the presence of HPV does not influence survival outcomes. Hence, there is no evidence to support a parallel transfer of therapy regimen for HPV-positive OPC to OSCC, in terms of therapy de-escalation and/or vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|